Fate Therapeutics (FATE) Sets New 1-Year High at $13.20
Fate Therapeutics Inc (NASDAQ:FATE) hit a new 52-week high during trading on Friday . The company traded as high as $13.20 and last traded at $11.37, with a volume of 494700 shares changing hands. The stock had previously closed at $11.37.
FATE has been the topic of a number of recent research reports. ValuEngine upgraded Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Zacks Investment Research upgraded Fate Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a research report on Tuesday, January 9th. Raymond James Financial reiterated a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, December 12th. Wedbush reiterated an “outperform” rating and issued a $7.00 target price (down previously from $10.00) on shares of Fate Therapeutics in a research report on Thursday, January 18th. Finally, Piper Jaffray Companies initiated coverage on Fate Therapeutics in a research report on Monday, December 18th. They issued an “overweight” rating and a $10.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $7.71.
The company has a market capitalization of $676.53, a PE ratio of -13.97 and a beta of 1.65. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.21 and a current ratio of 7.21.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.